Company Products Established Founder Distribution Production plants
|
|
- Shannon Jacobs
- 6 years ago
- Views:
Transcription
1 WOCKHARDT Wochardt ranks amongst India's leading pharma companies with a strong focus on biotech products. Background Wockhardt, is India's leading research based biotechnology, pharmaceuticals and health care enterprise. It traces its roots back to 1960s when the Mumbai-based Khorakiwala family bought a small pharmaceutical company that manufactured medicines for common cold and cough.till 1992, the company focused its operations towards becoming a major player in the Indian pharmaceutical industry.thereafter it concentrated its energies to become a global player. In 1998 it acquired Merind, a former affiliate of Merck Sharp and Dohme of the US.This enabled it to enter new therapeutic areas like corticosteroids, psychiatry and neurology. In the same year Wockhardt also acquired Wallis laboratory of the UK.Wockhardt acquired CP Pharmaceuticals in the United Kingdom in the year 2003, thereby gaining access to a large customer base of hospitals and the National Health Service (NHS). Largely due to these highly successful acquisitions, today it is the largest Indian pharmaceutical company in the UK and one of the top ten generic pharmaceutical companies in UK. The acquisition strategy continued in 2004 in Europe when Wockhardt acquired the brands, businesses and marketing infrastructure of Esparma GmbH of Germany. The manufacturing facilities of Wockhardt are spread across India and UK, with nine manufacturing plants in India and one in UK.These facilities have the approval of major regulatory bodies, including US FDA and UK's MHRA with capabilities for both finished dosage formulations and API.The state-of-the-art biotech park in Aurangabad is designed according to US FDA and EMEA (European Medicines Agency) standards.the company has subsidiaries in US, UK and Brazil, majority-owned companies in South Africa and Mexico and marketing offices in Africa, Russia, Central and South East Asia. The promoters hold the majority stake in the company (74.9 per cent of the equity stake).the next largest shareholders are the Indian public (11.2 per cent equity stake), followed by foreign institutional investors and overseas corporate bodies (5.1 per cent stake). Insurance companies, mutual funds, domestic financial institutions, banks, corporate bodies, non-resident Indians and shares representing GDRs constitute the remaining stake. Company Products Established Founder Distribution Production plants 194 Wockhardt Pharmaceuticals 1960 Khorakiwala India, Americas, India, UK Family Europe, Middle East, Asia Pacific, Africa
2 Product segment Diabetology Nephrology Pain Management Nutrition Neuro-Psychiatry Cough Therapy Power Brands Wosulin Mopaday Glimaday Wepox Proxyvon Spasmo-Proxyvon Methycobal Dexolac Decdan Libotryp Tryptomer Zedex Bro-Zedex Viscodyne Source: Company website presence in topicals (Nadifloxacin) and is among the worlds leading producers of API (Vitamin B12 and Dextromethorphan).Wockhardt has a significant presence in pain management, cough therapy, psychotic drugs, diabetology, vaccines, nutrition and animal health. It has embarked on a Power Brands strategy with a marketing emphasis on its brands that have contributed to significant market leadership. Wockhardt UK's oral healthcare products are sold both as own brand (ConfiDent) as well as private label to a large number of European retailers like Boots, Superdrug, Sainsbury, ASDA, Morrisons (UK), Kruidvat, Delhaize,VIP, Aldi, and Redwin (Global). Financial Analysis Products and Brands Wockhardt's market presence covers formulations, biopharmaceuticals, nutrition products, vaccines and API.The company has around 720 products in research driven fields such as diabetes, oncology, neurology, nephrology, infection, psychiatry, respiratory, cardiology, nutrition steriles, biotech, oral, topical and API. Wockhardt product portfolio constitutes two broad categories - generics and biotechnology. Its generic products include as Ranitidine, Enalapril, Famotidine and Bethanechol, which are marketed in the US.The company's biotechnology focus has resulted in the successful development and marketing of important recombinant products, namely Biovac (Hepatitis-B vaccine),wepox (recombinant Erythropoietin used in dialysis and for cancer patients) and Wosulin (recombinant insulin).the company has made a breakthrough with Interferon alpha 2b (an antiviral used in multiple sclerosis and cancer) and Glargine (a novel long-acting insulin). Growth stimulating factors (GSF) are in the development pipeline. It also has a Wockhardt's sales crossed the US$ 200 million mark in 2005, having witnessed a CAGR of 13.8 per cent between 2001 and Exports, which constitute more than 35 per cent of total sales grew at an impressive CAGR of 31 per cent during the same period.the company posted a CAGR of 32.5 per cent in its net profits in this period driven mainly by the increased scale in European markets due to integration of businesses and increased transactions in biotech business.the profitability margins have shown phenomenal increase in the year 2005 mainly on account of high savings in material cost, with operating margin at 31.2 per cent and net margin at 23.6 per cent.wockhardt is also in the midst of shifting a major portion of manufacturing of CP Pharma and Esparma to India, which shall yield further savings in manufacturing cost. Wockhardt's contribution in making Made in India global International business constitutes as much as 60 per cent of Wockhardt's revenue.the world's most sophisticated pharmaceutical markets, the US and 195
3 Europe, today account for about half of the company's turnover. For the last one decade, the company has been pursuing global business opportunities and growing by pitching itself against the world's most competitive players in generic pharmaceuticals.this has been made possible by pioneering research and successful acquisitions in potential markets. In Europe the company has identified exports, new product launches and strategic acquisitions as growth drivers. Its European presence consists of Wockhardt UK in the United Kingdom, formed after the integration of the two companies acquired by it,wallis Laboratory and CP Pharmaceuticals, and Esparma GmbH in Germany, acquired in In the US market Wockhardt has set up a sales and marketing subsidiary,wockhardt USA Inc., headquartered at New York, to enable it to capture greater value from its US operations.today, Wockhardt has six Abbreviated New Drug Application (ANDA) approvals in its pool - Famotidine, Ranitidine, Captopril, Enalapril, Bethanechol Chloride, and Cefuroxime Axetil. Another 50 ANDAs are in various stages of the developmental pipeline.the highlight of its US operations is its ascent to a leadership position in Bethanechol Chloride in the US market, garnering a 40 per cent market share. Wockhardt UK Limited is amongst the 10 largest generics companies in UK and the second largest hospital generics supplier. It has a US FDA approved manufacturing facility for injectables.this facility plays a strategic role in driving growth through partnerships in contract manufacturing. Wockhardt UK has entered into a product development and contract manufacturing relationship with Amylin Inc. for Exenatide. It has also built up a critical mass in private label overthe-counter drugs and dental care (denture cleaning tablets, powders and fixative creams).
4 Its German subsidiary Esparma GmbH has been identified as the vehicle for future acquisitions in the European market.the Esparma business was acquired with the brands, sales and marketing infrastructure sans the manufacturing facility and is expected to focus on neurology and urology, two high growth segments in Germany. In the emerging markets, the company has a presence through its subsidiary in Brazil, joint ventures in Mexico and South Africa as well as a market presence in Russia, Ukraine, Kazakhstan, Vietnam, Myanmar, Sri Lanka, Kenya, Ghana, Nigeria and Tanzania. Its subsidiary in Brazil,Wockhardt Farmaceutica Do Brazil Limited, was established in 2004 for marketing its generics and biotech products. Brazil is one of the world's top 10 generic markets, and is expected to emerge as a key market for Wockhardt after India, Europe and the US. Its joint venture in Mexico is with the country's leading national company to sell all forms of insulin manufactured by Wockhardt.This joint venture is planning to undertake marketing of other diabetology products and biopharmaceutical products at a later stage.the joint venture with Pharma Dynamics in South Africa has been formed for marketing Wockhardt's products in the country. Factors fuelling Wockhardt's global initiatives Aiding Wockhardt's globalisation plans are its ten world-class manufacturing plants and their state-ofthe-art research laboratories.wockhardt's global success has been made possible due to the technological advances brought about in the manufacturing set-up, to keep pace with requirements of global regulators like US FDA, MHRA and EMEA.The company has also established its own local offices in the US and Europe to coordinate its business with regulators. The insights gleaned from this experience are helping Wockhardt to interact with regulators in other potential markets. In the area of clinical trials Wockhardt has developed capabilities in undertaking successful trials.the trials on Wosulin, Asia's first recombinant insulin, marked a significant upward shift in Wockhardt's learning curve. For the first time, the trials were conducted as per ICH (The International Conference on Harmonisation of technical requirements for Registration of Pharmaceuticals for Human Use).These trials were unprecedented in Wockhardt's history and the learnings and insights gathered have been a competitive advantage for the company. The company's young and talented human resource pool, drawn from various countries, has been a great facilitator in transforming Wockhardt to the position it is today.the constant upgradation of their skill sets and globalisation of its work culture have helped Wockhardt in its globalisation plans. 197
5 Future plans The company has received 26 approvals for its biopharmaceutical products from 18 countries These would drive the growth of the biopharma division in the future.wockhardt does contract manufacturing for leading multinational companies in Europe and the US. plans in the biotech domain. It has targeted to launch one biotech product from its portfolio every year and expects its biotech sales to grow faster. It also intends to continue with its research orientation towards developing newer products for the market. 198 Wockhardt is also in the process of expanding its dermatology business. It has made a sound beginning by gaining exclusive marketing rights for their Nadifloxacin brand (Nadoxin).This drug is not only an effective treatment for a wide range of tropical bacterial infections but has also proven ability against Mupirocin and Fusidic acid-resistant strains. The company has recently received approval from US FDA for marketing Zonisamide capsules in the US market. Zonisamide is the generic version of Dainippon's Zonegran capsules with a market size of US$ 174 million. Given that Wockhardt has developed competence in the biotech segment, it has laid down aggressive Globalisation at a glance Revenues from international markets constitute nearly 60 per cent of total sales, with most of them coming from US and Europe Six ANDA approvals for drugs in its portfolio in the US Acquisitions of 3 international pharma companies - 2 in UK and 1 in Germany Subsidiaries in US, UK, Germany and Brazil Market presence in Russia, Ukraine, Kazakhstan, Vietnam, Myanmar, Sri Lanka, Kenya, Ghana, Nigeria and Tanzania Subsidiary in UK amongst the top 10 generic companies in the country
PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)
PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) COPY Date : 23-02-2010 News / Story reproduced with thanks:- Stockmarkest.com Indian pharmaceutical industry has
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationBackground. Past, present and future of Intas
Background Mr. Hasmukh K. Chudgar, is the Chairman of Intas Pharmaceuticals Limited. In the early 1980s, having witnessed the growing healthcare challenges, he envisioned a future of quality healthcare
More informationManagement Discussion and Analysis for the Third quarter of FY
Management Discussion and Analysis for the Third quarter of FY 2012-13 Revenue Figures Consolidated INR in Millions Third quarter ended Dec 31, Nine months ended Dec 31 FY 2012-13 FY 2011-12 Growth % FY
More informationManagement Discussion and Analysis for the First quarter of FY
Management Discussion and Analysis for the First quarter of FY 2015 16 Revenue Figures Consolidated (Rs. In Millions) Q1 FY 2015-16 Q1 FY 2014-15 Growth % India 4,729.30 3,971.59 19.08% US 5,610.46 4,886.70
More informationCadila Healthcare Ltd. Investor Presentation February 2010
Cadila Healthcare Ltd. Investor Presentation February 2010 1 Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve
More informationCadila Healthcare Ltd. Investor Presentation August 2010 BSE : NSE : CADILAHC 1
Cadila Healthcare Ltd. Investor Presentation August 2010 BSE : 532321 NSE : CADILAHC 1 Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1
More informationLeading domestic players in India s pharmaceutical market in 2015
THE INDIAN PHARMACEUTICAL MARKET LEADING DOMESTIC COMPANIES 2015 Leading domestic players in India s pharmaceutical market in 2015 1 Executive Summary 1.1 Executive Summary 1.2 Research and Analysis Methods
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION About us. Established in 1973, Micro Labs is a fully integrated pharmaceutical company, present across the entire pharmaceutical value chain from Research and Development, Active
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationPROFILE OF an EmERgIng GLOBAL LEADER
PROFILE OF an emerging GLOBAL LEADER 1 2 Today is the beginning of an exciting journey at Sun Pharma. With two companies coming together, we are creating a new organization that will be better than the
More informationMoving from volume to value in the generic business model
Moving from volume to value in the generic business model CPhI Pre-connect conference Frankfurt 23rd October 2017 Copyright 2016 QuintilesIMS. All rights reserved. Key drivers to 2021 Global growth moderating
More informationCompany Research. Dr Reddy s Laboratories- BUY with a Target of Rs 1,962. Investment overview- Business Overview-
Date-16-07-2012 Dr Reddy s Laboratories- BUY with a Target of Rs 1,962 Investment overview- Shareholders Information Global Generics grew by 68% to Rs 70,243mn in FY12 from Rs 53,340mn in Fy11. Therefore
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation June 2018 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.2% With a Global Footprint Revenue
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationHealth Care Worldwide. Crédit Suisse Global Credit Products Conference October 1, Barcelona
Health Care Worldwide Crédit Suisse Global Credit Products Conference October 1, 2015 - Barcelona Safe Harbor Statement This presentation contains forward-looking statements that are subject to various
More informationMayne Group Limited. ABN AMRO Global Generic Pharmaceutical Conference. Mr Mark Bisset Vice President Global Business Development
Mayne Group Limited ABN AMRO Global Generic Pharmaceutical Conference Mr Mark Bisset Vice President Global Business Development 9 March 2005 Mumbai, India Forward-Looking Statement Comments will be made
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health January 2018 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation September 2017 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.4% With a Global Footprint Revenue
More informationDr. Reddy s at a glance
Dr. Reddy s at a glance 22000 people 40 nationalities 200 products 30 countries One Purpose We accelerate access to affordable and innovative medicines because Dr. Reddy s at a glance 8/22/2017 2 Our Purpose
More informationWORKING CAPITAL MANAGEMENT: A STUDY ON INDIAN PHARMA COMPANIES
ISSN (Print): 30-5504 ISSN (Online): 347-4793 WORKING CAPITAL MANAGEMENT: A STUDY ON INDIAN PHARMA COMPANIES Sri Ayan Chakraborty Faculty: Management: University Program (Techno India University), ICA
More informationa thousand smiles. in one celebration. Life.
a thousand smiles. in one celebration. a thousand milestones. in one journey. Established in 1953, Biological E Limited (BE) is a leading, world-class Pharmaceutical and Biologics company with an impressive
More informationCadila Healthcare Ltd. Investor Presentation November 2010 BSE : NSE : CADILAHC 1
Cadila Healthcare Ltd. Investor Presentation November 2010 BSE : 532321 NSE : CADILAHC 1 Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation March 2018 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.2% With a Global Footprint Revenue
More informationCompany Products Established Founder Distribution Production plants
WIPRO Wipro has emerged as one of the major Indian global brands in the area of IT consulting services. Background Wipro Limited (formerly Western India Vegetable Products Limited) was incorporated in
More informationManagement Discussion and Analysis for the Second quarter of FY
Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion
More informationManagement Discussion and Analysis for the Financial Year Q1FY Revenue Figures Consolidated Q1 - FY
Management Discussion and Analysis for the Financial Year Q1FY 2013-14 Revenue Figures Consolidated Q1 - FY 2013-14 INR in Millions Q1- FY 2012-13 Growth % Speciality Business India 3,285.83 2,797.88 17.44%
More informationInvestor Presentation Q1FY
Investor Presentation Q1FY19 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements".
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationChallenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015
Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationANNUAL INVESTOR CONFERENCE st May 2013, Mumbai
ANNUAL INVESTOR CONFERENCE 2013 21st May 2013, Mumbai RPG Group $3 bn Global & diversified Indian business group TYRE INFRASTRUCTURE Presence in key sectors of economy SPECIALITY IT 2 Group Vision We shall
More informationUnderstanding How The Indian Pharmaceutical Industry Works Part 3
Understanding How The Indian Pharmaceutical Industry Works Part 3 Key Performance Indicators Pharmaceutical Sector Sales & Marketing Marketing always starts with the customer and ends with the customer
More informationCompany Profile. German-Taiwan Biotech Seminar 6 November 2017
Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationFORWARD THINKING HEALTHCARE
AT A 2018 GLANCE 02 FORWARD THINKING HEALTHCARE Fresenius is a global healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 270,000 employees
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation March 2017 A Leading Pharmaceutical Company #4 Leading pharmaceutical company in India 1 Market share of 4.2% With a Global Footprint Revenue Split for 9MFY17
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation November 2017 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.3% With a Global Footprint Revenue
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationCompany Products Established Founder Distribution Production plants
UNITED PHOSPHORUS UPL has sucessfully transformed itself froma domestic insecticide player to a global generic agrochemicals player. Background UPL Limited (UPL), incorporated in 1969 as a domestic insecticide
More informationCipla products are bought by over 180 countries located in the following regions:
Date: 16/12/2010 CORPORATE INFORMATION: During the fiscal year ended March 31, 2010, the Company introduced a number of new drugs and formulations, such as Advent Forte (amoxicillin and clavulanic acid
More informationAPI Production in Developing Countries Bangladesh Experience
International Conference on Local Pharmaceutical Production in Africa, Cape Town. API Production in Developing Countries Bangladesh Experience Muhammadul Haque Executive Director, Marketing Square Pharmaceuticals
More informationNew Man International Journal of Multidisciplinary Studies (ISSN: ) Mohd Azhar-Ud-Din Malik Research Scholars Jiwaji Unversity Gwalior (M.
Abstract 8. INDIAN PHARMACEUTICAL INDUSTRIAL CONTRIBUTION AND COMPETITION Mohd Azhar-Ud-Din Malik Research Scholars Jiwaji Unversity Gwalior (M.P) Biotechnology has become a source of earning for many
More informationCadila Healthcare Ltd. Investor Presentation June 2011 BSE : NSE : CADILAHC 1
Cadila Healthcare Ltd. Investor Presentation June 2011 BSE : 532321 NSE : CADILAHC 1 Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline; Stepping beyond the billion,
More informationDealdoc. Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon.
Dealdoc Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon Oct 18 2010 Marketing agreement for Recombinant Human Insulin, Glargine, Aspart
More informationMargins of pharmaceutical companies are continuing to decline the future lies in new ecosystems
Karin Mateu Media Relations Tel.: +41 (0) 58 286 44 09 karin.mateu@ch.ey.com Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Glaxo is leading the way in
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationIndia as an Outsourcing Frontier in Biotechnology
1 India as an Outsourcing Frontier in Biotechnology K.V. Subramaniam President & CEO 3 rd Annual Biotech Supply Chain Academy Conference San Francisco Oct 26, 2010 Biotechnology Industry Issues Long gestation
More informationManagement Discussion and Analysis for the Financial Year Q3 FY
Management Discussion and Analysis for the Financial Year Q3 FY 2011-12 Revenue Figures Consolidated INR in Millions Third quarter ended Dec 31 Nine months ended Dec 31 Q3 - FY 2011-12 Q3- FY 2010-11 Growth
More informationCadila Healthcare Limited Investor Presentation November 2012
Cadila Healthcare Limited Investor Presentation November 2012 Well integrated pharma player with global footprints ~60 years Operational experience $ 1 bn + Global Revenues >6% of sales Spent on R&D annually
More informationAUROBINDO S EUROPEAN OPERATIONS BINDING AGREEMENT TO ACQUIRE GENERIS IN PORTUGAL. January 2017
AUROBINDO S EUROPEAN OPERATIONS BINDING AGREEMENT TO ACQUIRE GENERIS IN PORTUGAL January 2017 Forward Looking Statements This presentation contains statements that constitute forward looking statements
More informationWest Pharmaceutical Services, Inc. J.P. Morgan Healthcare Conference. Eric M. Green, President & CEO January 9, 2019
West Pharmaceutical Services, Inc. J.P. Morgan Healthcare Conference Eric M. Green, President & CEO January 9, 2019 Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform
More informationList of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1
Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted
More information4P-Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
4P-Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile. 4P-Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile. BioPortfolio has been marketing business and market
More informationMarketing Director December 01, 2007 BASF (Bangladesh) Ltd. Till date
Arshad-ul-Alam House-14, Road-4, DOHS (Banani) Dhaka Cantonment, Dhaka-1206, Bangladesh Tel: (8802) 8827183, 9899937, 01730012788, 01711594542 e-mail: arshadul7@dhaka.net CAREER BACKGROUND Marketing Director
More informationManagement Discussion and Analysis for the Financial Year Q1 FY
Management Discussion and Analysis for the Financial Year Q1 FY 2012-13 Revenue Figures Consolidated Q1 - FY 2012-13 INR in Millions Q1- FY Growth 2011-12 % Speciality Business India 2797.88 2253.82 24.14%
More informationCOLLABORATION WITH MYLAN TO COMMERCIALIZE BIO-GENERICS
DISCLAIMER Certain statements in this release concerning our future growth prospects are forward looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause
More informationL A B O R M A R K E T B R I E F I N G S S E R I E S
L A B O R M A R K E T B R I E F I N G S S E R I E S LABOR MARKET INFORMATION FOR RESEARCHERS THE LIFE SCIENCE AND PHARMACEUTICALS SECTOR IN EUROPE L I F E S C I E N C E A N D P H A R M A C E U T I C A
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationPortfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO
Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationCollaborative Procedure to Accelerate Medicines Registration
Collaborative Procedure to Accelerate Medicines Registration Pharmaceuticals Limited Mumbai, INDIA Challenging the Frontiers in Healthcare Outline Introduction to Macleods Pharma. Regulatory filings by
More informationFresenius Investor News
health care worldwide October 31, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More information2009 INVESTOR DAY. BioPharmaceuticals. Ken Frank President BioPharmaceuticals December 17, Sustainable, Profitable Growth
2009 INVESTOR DAY BioPharmaceuticals Ken Frank President BioPharmaceuticals December 17, 2009 Sustainable, Profitable Growth Life Sciences FY 2009 Total Sales $2,329.2 (amounts shown in millions) BioPharmaceuticals
More informationSciGen Limited. Annual General Meeting Managing Director s Presentation. 28 February 2005
SciGen Limited Annual General Meeting Managing Director s Presentation 28 February 2005 Mr Mark Compton Chief Executive Officer and Managing Director SciGen Limited Biopharmaceutical company Expert focus
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationImmatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been
More informationAnnual Meeting of Shareholders
Annual Meeting of Shareholders Edward J. Ludwig Chairman and Chief Executive Officer February 3, 2009 Agenda Corporate Strategy Performance Trends Growth Drivers 2 Corporate Strategy Drive Revenue Growth
More informationCadila Healthcare Limited Investor Presentation August 2014
Cadila Healthcare Limited Investor Presentation August 2014 Well integrated pharma player with global footprints >60 years Operational experience $ 1 bn + Global Revenues ~ 7% of sales Spent on R&D annually
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationInnovative Science Affordable Medicine
Innovative Science Affordable Medicine H1 FY13 Results Presentation : Oct 31, 2012 www.biocon.com Overall Financial Performance H1 FY13 H1 FY12 % Growth Revenue 1,235 1,001 23% EBITDA 305 281 8% 25% 28%
More informationSciClone Pharmaceuticals, Inc. (SCLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SciClone Pharmaceuticals, Inc. (SCLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile SciClone Pharmaceuticals, Inc. (SCLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
More informationFor personal use only
ANNUAL GENERAL MEETING MINTER ELLISON LEVEL 23, 525 COLLINS ST, MELBOURNE VIC 3000 AT 11.00 AM ON 26 NOVEMBER, 2014 CEO S ADDRESS Thank you Roger. Good morning Ladies and Gentlemen. It is a pleasure to
More informationAsia A New Frontier for Clinical Research and Development
Asia A New Frontier for Clinical Research and Development Executive Summary As the pharmaceutical market experiences rapid growth in Asia, more clinical trials are being conducted in the region, offering
More informationUnither Pharmaceuticals - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Unither Pharmaceuticals - Pharmaceuticals & Healthcare - Deals and Alliances Profile Unither Pharmaceuticals - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More information37 th. Annual General Meeting. July 24, 2015 Biocon Research Centre. Chairperson s Speech. Kiran Mazumdar Shaw, Chairperson & Managing Director
37 th Annual General Meeting July 24, 2015 Biocon Research Centre Chairperson s Speech Kiran Mazumdar Shaw, Chairperson & Managing Director Welcome Biocon marks another successful year of providing affordable
More informationCompany Presentation. Jefferies Healthcare Conference, London November 2014
Company Presentation Jefferies Healthcare Conference, London November 2014 Important Disclosure Materials and information provided during this presentation may contain forward-looking statements. These
More informationSustained impetus across verticals drives Biocon s Q1 growth
Bangalore, India July 25, 2012 Sustained impetus across verticals drives Biocon s Q1 growth Revenues at ` 593 Crores; EBITDA at ` 139 Crores; PAT at ` 79 Crores Commenting on the results, Chairman and
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationAnti Infective Pharmaceuticals Market India
Anti Infective Pharmaceuticals Market India April 2012 Eecutive Summar Market Drivers and Challenges Drug Regulation and Patents Global anti infective pharmaceuticals market was valued at INR. units while
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More informationJefferies 2016 Healthcare Conference. June 7, 2016
Jefferies 2016 Healthcare Conference June 7, 2016 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management
More informationWelcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese
More informationAstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review
AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationGrupo Indukern in facts
PRESS RELEASE Grupo Indukern in facts Multinational family-owned group. Founded in 1962 by José Luis Díaz-Varela. Comprises three main companies : INDUKERN Chemical Sector, Calier Veterinary Laboratory
More informationWelcome to the 2007 Annual Meeting of Stockholders
Welcome to the 2007 Annual Meeting of Stockholders Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform
More informationFresenius Investor News
health care worldwide August 3, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationFinancial Results Meeting: FY Ended March 2013
Financial Results Meeting: FY Ended March 2013 (April 1, 2012 - March 31, 2013) May 10, 2013 Kintetsu World Express, Inc. 0 Contents Summary of Business Results for FY ended March 31, 2013, and Forecast
More informationAlmac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
More informationPolicies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More informationAKRIKHIN: COMPANY PRESENTATION
AKRIKHIN: COMPANY PRESENTATION AKRIKHIN OVERVIEW (1) Akrikhin at a glance Member of Polpharma Group Market position In ТОP 10 largest Russian manufacturers with a turnover more than $200 millions in 2013
More informationVisiongain. -v1531/ Publisher Sample
Visiongain http://www.marketresearch.com/visiongain -v1531/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST Fridays:
More informationALKENZ. P h a r m a c e u t i c a l
ALKENZ P h a r m a c e u t i c a l OUTLINE About us. Our vision. Our mission. Our services. Our partners. Target Markets. Product Portfolio Design. Registration Department. Distribution. Local/Regional
More informationat a glance Lugano, 20 September 2013 LUGANO SMALL & MID CAP INVESTOR DAY > 50 years of Pharmaceutical & Life Science Services IV Edizione
at a glance LUGANO SMALL & MID CAP INVESTOR DAY IV Edizione Hotel Splendide Royal 20 settembre 2013 Lugano, 20 September 2013 Pierrel S.p.A. Pierrel S.p.A. is listed on the Italian Stock Exchange (MTA)
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationBiocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr
Press Release Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr FY18 Revenue Rs 4,336 Cr; EBITDA at Rs 1,035 Cr; Net Profit at Rs 372 Cr Bengaluru, Karnataka,
More informationInvestor Presentation
Investor Presentation November 2016 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe harbor statement This presentation contains forward-looking statements and
More information